Aroflo®-100 Arocap: Each inhalation capsule contains Salmeterol Xinafoate BP equivalent to Salmeterol 50 μg and Fluticasone Propionate BP 100 μg.
Aroflo®-250 Arocap: Each inhalation capsule contains Salmeterol Xinafoate BP equivalent to Salmeterol 50 μg and Fluticasone Propionate BP 250 μg.
Aroflo®-500 Arocap: Each inhalation capsule contains Salmeterol Xinafoate BP equivalent to Salmeterol 50 μg and Fluticasone Propionate BP 500 μg.
Aroflo® Arocap is a combination of Salmeterol and Fluticasone Propionate. Salmeterol is a selective, long acting ß2-agonist used in the treatment of asthma and other forms of diffuse airways obstruction. Fluticasone Propionate is a corticosteroid with potent anti-inflammatory activity. Fluticasone Propionate is stated to exert a topical effect on the lungs without systemic effects at usual dose.
Asthma:
Aroflo Arocap is indicated in the regular treatment of asthma where use of a combination product (long-acting ß2-agonist and inhaled corticosteroid) is appropriate:
Chronic Obstructive Pulmonary Disease (COPD):
Aroflo Arocap is indicated for the symptomatic treatment of patients with COPD, with a FEV1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.
Asthma:
COPD:
Both non-selective and selective ß-blockers should be avoided in patients with asthma, unless there are compelling reasons for their use. Care should be taken while co-administering of CYP3A4 inhibitors (i.e. Ketoconazole, Ritonavir) & Salmeterol-Fluticasone as there is an increased risk of systemic side effects of individual component.
Aroflo® Arocap is contraindicated in patients with hypersensitivity to any of the active substances or to the excipients of this preparation.
As Aroflo® Arocap contains Salmeterol and Fluticasone Propionate, the type and severity of adverse reactions associated with each of the compounds may be expected. There is no incidence of additional adverse events following concurrent administration of the two compounds. The pharmacological side effects of ß2-agonist treatment, such as tremor, palpitations and headache have been reported, but tend to be transient and reduce with regular therapy. Cardiac arrythmia may occur. There have been reports of arthralgia and hypersensitivity reactions, including rash, oedema and angioedema. There have been reports of oropharyngeal irritation. Due to the Fluticasone Propionate component, hoarseness and candidiasis (thrush) of the mouth and throat can occur in some patients. Both hoarseness and incidence of candidiasis may be relieved by gargling with water after using the product. Symptomatic candidiasis can be treated with topical anti-fungal therapy whilst still continuing with the Aroflo® Arocap Dry Powder Inhalation Capsule. Possible systemic effects in children include adrenal suppression, growth retardation, decrease in bone mineral density.
Use in pregnancy: There are insufficient data on the use of Salmeterol & Fluticasone Propionate during pregnancy. Administration of drugs to pregnant women should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus.
Use in lactation: There are no data available for human breast milk. Administration of Salmeterol & Fluticasone Propionate to women who are breast-feeding should only be considered if the expected benefit to the mother is greater than any possible risk to the child.
Special patient groups: There is no need to adjust the dose in elderly patients or in those with renal impairment. There are no data available for use of Aroflo® Arocap in patients with hepatic impairment.
Aroflo® Arocap should not be used to treat acute asthma symptoms for which a fast and short acting bronchodilator is required. Aroflo® Arocap should not be stopped abruptly. It should be administered with caution in patients with pulmonary tuberculosis. Aroflo® Arocap should be used with caution in patients with severe cardiovascular disorders, heart rhythm abnormalities, diabetes mellitus, thyrotoxicosis, uncorrected hypokalemia or patients predisposed to low levels of serum potassium. Systemic effects may occur with any inhaled corticosteroid, particularly at high doses prescribed for long periods. These effects are much less likely to occur than with oral corticosteroids. It is important, therefore, that the patient is reviewed regularly and the dose of inhaled corticosteroid is reduced to the lowest dose at which effective control of asthma is maintained.
Store below 30 C, keep in dry place & protect from light. Keep out of the reach of children.